Summary
The effect of multidisciplinary therapy for hepatocellular carcinoma (HCC) was evaluated in 121 resected cases. The 5-year survival was 100% for absolute curative resection (12 cases), 59.1% for relative curative resection (n-37) and 10.9% for relative non-curative resection (n=59). However, none of the patients survived for more than 3 years after absolute non-curative resection (n-13). The non-recurrence in the preoperative TAE groups was different from that in non-TAE groups under-going absolute and relative curative resection. The 1- and 3-year non-recurrence rates for relative non-curative resection were 92.3% and 53.8%, respectively, for the preoperative TAE group and 56.1% and 28.1%, respectively for the non-TAE group. These data show that preoperative TAE is effective in relative non-curative resection. Functional disturbances of the coagulation-fibrinolysis system in cirrhotic patients were improved after PSE. All patients undergoing hepatectomy after PSE had an uneventful postoperative course, including well-maintained function of the coagulation-fibrinolysis system and a decrease in splenic volume. At 1 year after hepatectomy, cirrhotic patients with critical liver function and poor coagulation-fibrinolysis showed appreciable hepatic regeneration. One patients died of hepatic failure 1 year after the operation. In recurrent HCC, the 1-, 2- and 3-year survivial values after reresection were 100%, 75.0% and 25.0%, respectively. The respective values following TAE were 79.0%, 42.0% and 9.0%. Three cases of recurrent HCC were effectively treated, i.e., two patients achieved a partial response and one showed no change, by continuous intra-arterial infusion of 5-FU and lentinan with intermittent one-shot injections of epirubicin using a subcutaneous infusion pump. These three patients are alive at 1 year and 7 months, 1 year and 4 months and 6 months after the treatment, respectively.
Similar content being viewed by others
References
Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F, Kondo Y (1990) Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastrohepatol 5, 616
Fujiwara S, Okamoto E, Yamanaka N, Katoh T, Manabe Y, Furukawa K, Kawamura E (1990) Importance of multidisciplinary treatment for hepatocellular carcinoma (in Japanese). J Jpn Surg Soc 91: 1375
Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J, Ishiguro S, Ohigashi H, Ishikawa O, Fukuda I, Furukawa H, Koyama H, Iwanaga T (1989) A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 23 (Suppl): S126
Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S, Hasuo K (1984) Selective effects of lipiodolized antitumor agents. J Surg Oncol 25: 218
Liver Cancer Study Group of Japan (1987) Primary liver cancer in Japan, Sixth report. Cancer 60: 1400
Liver Cancer Study Group of Japan (1989) The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19: 98
Mizumoto R, Kawarada Y, Noguchi T (1979) Preoperative estimation of operative risk in liver surgery, with special reference to functional reserve of the remnant liver following major hepatic resection. Jpn J Surg 9: 343
Miura T (1989) Treatment of hepatic cancer by hepatic arterial infusion chemotherapy. Cancer Chemother Pharmacol 23 (Suppl): S121
Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Chang YC, Niimi K (1986) Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg 73: 434
Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M (1986) Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 58: 1001
Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y (1989) Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleuking-2 in patients with unresectable hepatocellular carcinoma. Hepatology 10: 349
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485
Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y (1989) Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. Am J Gastroenterol 84: 1400
Sheu JC, Sung JL, Huang GT, Chen DS, Yang PM, Lai MY, Wei TC, Su CT, Tsang YM, Lee CZ, Chen JC, Hsu HC (1987) Intratumor injection of absolute ethanol under ultrasound guidance for the treatment of small hepatocellular carcinoma. Hepatogastroenterology 34: 255
Shiina S, Tagawa K, Unuma T, Terano A (1990) Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR 154: 947
Yamazaki S, Makuuchi M, Hasegawa H (1988) Multidisciplinary therapy for hepatocellular carcinoma (in Japanese). Rinsho Kagaku 24: 732
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawarada, Y., Imai, T., Iwata, M. et al. Significance of multidisciplinary therapy for hepatocellular carcinoma. Cancer Chemother. Pharmacol. 31 (Suppl 1), S13–S19 (1992). https://doi.org/10.1007/BF00687098
Issue Date:
DOI: https://doi.org/10.1007/BF00687098